Cinctive Capital Management LP Buys Shares of 89,822 Amedisys, Inc. (NASDAQ:AMED)

Cinctive Capital Management LP bought a new stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 89,822 shares of the health services provider's stock, valued at approximately $8,155,000. Cinctive Capital Management LP owned 0.27% of Amedisys at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Trexquant Investment LP raised its position in Amedisys by 1,317.8% during the 4th quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider's stock worth $7,964,000 after buying an additional 81,532 shares during the last quarter. National Bank of Canada FI lifted its position in Amedisys by 119.0% in the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider's stock valued at $5,365,000 after purchasing an additional 30,213 shares during the period. ABC Arbitrage SA purchased a new stake in Amedisys in the 4th quarter valued at approximately $2,522,000. Geode Capital Management LLC increased its position in Amedisys by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider's stock worth $54,746,000 after purchasing an additional 7,071 shares during the period. Finally, Quarry LP acquired a new position in Amedisys during the 3rd quarter worth approximately $2,569,000. Hedge funds and other institutional investors own 94.36% of the company's stock.

Amedisys Price Performance

AMED stock traded down $0.79 during trading on Monday, reaching $91.11. 123,267 shares of the company were exchanged, compared to its average volume of 397,268. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The stock's 50 day moving average price is $92.31 and its 200 day moving average price is $92.25. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The company has a market cap of $2.99 billion, a P/E ratio of 36.15, a PEG ratio of 1.78 and a beta of 0.89.

Remove Ads

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $598.05 million for the quarter, compared to analysts' expectations of $602.38 million. As a group, analysts predict that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Stephens reissued an "equal weight" rating and issued a $101.00 price target on shares of Amedisys in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat, Amedisys has an average rating of "Hold" and an average price target of $101.00.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.